In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
Black women with chronic myeloid leukemia face unique challenges when it comes to diagnosis, treatment, and overall disease ...
Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...
Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback